Here’s what you should know.
1. Allergan’s linaclotide delayed release clinical data will focus on abdominal pain in irritable bowel syndrome with constipation.
2. Its Linzess data will focus on treatment satisfaction comparing an indirect treatment comparison and stool consistency and frequency data.
3. Allergan’s Viberzi data will focus on the drug’s effectiveness in treating irritable bowel syndrome with diarrhea.
4. Finally, its relamorelin data will focus on gastroparesis and cenicriviroc products to treat non-alcoholic steatohepatitis.
More articles on gastroenterology:
Gastrointestinal Specialists join Hampton Physicians Group — 3 insights
Gastro Health acquires Dr. Orlando Torres’ practice: 3 key notes
GI leader to know: Dr. Stephen Hutto of NorthPark Medical Plaza
